Comparison of the Efficacy of Posaconazole Delayed Release Tablets and Suspension in Pediatric Hematology/Oncology Patients

Overview

Journal J Pediatr Pharmacol Ther

Specialty Pediatrics

Date 2020 Jan 4

PMID 31897075

Citations 4

Authors

Erika N Wass

Elvin A Hernandez

Caroline M Sierra

Affiliations

Soon will be listed here.

Abstract

Objectives: Posaconazole is effective in preventing invasive fungal infections in neutropenic pediatric patients. The oral suspension has challenges in administration and absorption that are theorized to be minimized with delayed release tablets. However, this has not been validated in the pediatric population. This study was conducted to compare the efficacy and safety of posaconazole suspension and delayed release tablets in pediatric hematology/oncology patients.

Methods: A retrospective chart review in pediatric hematology/oncology patients was conducted from February 2013 to February 2017. Data collected include patient demographic data; posaconazole formulation, dose, and serum concentrations; and adverse events.

Results: Sixty-five patients with 353 serum posaconazole concentrations were included; 51.6% of concentrations drawn while patients were receiving posaconazole suspension were therapeutic, whereas 62.5% of concentrations drawn while patients were receiving posaconazole delayed release tablets were therapeutic (p = 0.035). Serum concentrations drawn while taking acid suppression (histamine receptor antagonists or proton pump inhibitors) and posaconazole suspension were less likely to be therapeutic (p < 0.0001) compared with those taken while receiving delayed release tablets. Adverse event profiles were similar between both formulations.

Conclusions: Delayed release tablets proved more effective in achieving therapeutic serum posaconazole concentrations than posaconazole suspension, with minimal difference in adverse events, in pediatric hematology/oncology patients.

Citing Articles

The effectiveness and safety of posaconazole enteric-coated tablet versus oral suspension in invasive fungal infections.

Yang Y, Yi Q, Han Y, Li Y, Yang R Sci Rep. 2024; 14(1):27887.

PMID: 39538016 PMC: 11561054. DOI: 10.1038/s41598-024-79512-x.

Therapeutic drug monitoring of posaconazole delayed-release tablets and injections in pediatric patients.

Wu J, Chen C, Luo C, Ning B, Liu Y, Li Z Antimicrob Agents Chemother. 2024; 68(12):e0111224.

PMID: 39503485 PMC: 11619399. DOI: 10.1128/aac.01112-24.

Antifungal Prophylaxis With Posaconazole in Immunocompromised Children Younger Than 13 Years.

Maquera-Afaray J, Luna-Vilchez M, Salazar-Mesones B, Portillo-Alvarez D, Uribe-Ramirez L, Taipe-Sedano G J Pediatr Pharmacol Ther. 2022; 27(1):57-62.

PMID: 35002560 PMC: 8717622. DOI: 10.5863/1551-6776-27.1.57.

Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Model of () Infection.

Fernandez O, Rosales-Chilama M, Quintero N, Travi B, Wetzel D, Gomez M Antimicrob Agents Chemother. 2021; 66(1):e0142521.

PMID: 34694879 PMC: 8765415. DOI: 10.1128/AAC.01425-21.

References

Doring M, Eikemeier M, Cabanillas Stanchi K, Hartmann U, Ebinger M, Schwarze C . Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis. 2015; 34(6):1189-200. PMC: 4426129. DOI: 10.1007/s10096-015-2340-y. View

Pettit N, Miceli M, Rivera C, Narayanan P, Perissinotti A, Hsu M . Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017; 72(8):2355-2358. PMC: 5890703. DOI: 10.1093/jac/dkx122. View

Belling M, Kanate A, Shillingburg A, Lu X, Wen S, Shah N . Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leuk Res Treatment. 2017; 2017:3460892. PMC: 5485328. DOI: 10.1155/2017/3460892. View

Tverdek F, Heo S, Aitken S, Granwehr B, Kontoyiannis D . Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. Antimicrob Agents Chemother. 2017; 61(8). PMC: 5527592. DOI: 10.1128/AAC.00188-17. View

Doring M, Blume O, Haufe S, Hartmann U, Kimmig A, Schwarze C . Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2013; 33(4):629-38. PMC: 3953550. DOI: 10.1007/s10096-013-1998-2. View

Science M, Robinson P, MacDonald T, Rassekh S, Dupuis L, Sung L . Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014; 61(3):393-400. DOI: 10.1002/pbc.24847. View

Doring M, Cabanillas Stanchi K, Queudeville M, Feucht J, Blaeschke F, Schlegel P . Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2017; 143(7):1281-1292. DOI: 10.1007/s00432-017-2369-7. View

Kersemaekers W, Dogterom P, Xu J, Marcantonio E, de Greef R, Waskin H . Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015; 59(6):3385-9. PMC: 4432131. DOI: 10.1128/AAC.05000-14. View

Liebenstein T, Widmer K, Fallon M . Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation. J Oncol Pharm Pract. 2017; 24(8):599-603. DOI: 10.1177/1078155217722405. View

10.

Vanstraelen K, Colita A, Bica A, Mols R, Augustijns P, Peersman N . Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area. Pediatr Infect Dis J. 2015; 35(2):183-8. DOI: 10.1097/INF.0000000000000963. View

11.

Welch S, Pallotta A, Weber C, Siebenaller C, Cober E, Neuner E . Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre. Mycoses. 2016; 60(4):241-243. DOI: 10.1111/myc.12587. View

12.

Doring M, Muller C, Johann P, Erbacher A, Kimmig A, Schwarze C . Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis. 2012; 12:263. PMC: 3514296. DOI: 10.1186/1471-2334-12-263. View

13.

Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M . Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob Agents Chemother. 2015; 59(8):4424-8. PMC: 4505228. DOI: 10.1128/AAC.00581-15. View

14.

Bernardo V, Cross S, Crews K, Flynn P, Hoffman J, Knapp K . Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother. 2013; 47(7-8):976-83. PMC: 4384822. DOI: 10.1345/aph.1R775. View

15.

Pham A, Bubalo J, Lewis 2nd J . Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant. Antimicrob Agents Chemother. 2016; 60(11):6945-6947. PMC: 5075114. DOI: 10.1128/AAC.01489-16. View

16.

Vehreschild J, Muller C, Farowski F, Vehreschild M, Cornely O, Fuhr U . Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012; 68(6):987-95. DOI: 10.1007/s00228-012-1212-y. View

17.

Soysal A . Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infect Drug Resist. 2015; 8:321-31. PMC: 4573198. DOI: 10.2147/IDR.S65592. View

18.

Dekkers B, Bakker M, van der Elst K, Sturkenboom M, Veringa A, Span L . Therapeutic Drug Monitoring of Posaconazole: an Update. Curr Fungal Infect Rep. 2016; 10:51-61. PMC: 4896980. DOI: 10.1007/s12281-016-0255-4. View